SCHEMBL11944367

SCHEMBL11944367

CCCS(=O)(=O)N1CCN(c2cnn(-c3ccccn3)c(=O)c2O[C@@H]2CCC[C@H]2C)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ MAPT P10636 2/20 0.44
▸ GLA P06280 1/20 0.40
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ GPR119 Q8TDV5 8/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ GRM7 Q14831 3/20 0.35
▸ HTR4 Q13639 1/20 0.35
▸ SLC2A1 P11166 1/20 0.35
▸ SLC2A2 P11168 1/20 0.35
▸ SLC2A3 P11169 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11944290 0.89 MAPT (0.41) KDM4EHSD17B10ALDH1A1POLBHPGD
SCHEMBL11944193 0.89 ALDH1A1 (0.45) KDM4EHSD17B10ALDH1A1HPGDMAPT
SCHEMBL11944312 0.87 CA12 (0.39) KDM4EHSD17B10ALDH1A1KMT2AMAPT
SCHEMBL11944170 0.83 MAPT (0.44) KDM4EHSD17B10ALDH1A1KMT2APOLB
SCHEMBL11944164 0.80 KDM4E (0.39) KDM4EHSD17B10ALDH1A1KMT2AMAPT
SCHEMBL11944001 0.76 ALDH1A1 (0.48) KDM4EHSD17B10ALDH1A1HPGDMAPT
SCHEMBL11945164 0.76 MAPT (0.42) KDM4EHSD17B10ALDH1A1POLBHPGD
SCHEMBL11945074 0.76 MAPT (0.41) KDM4EHSD17B10ALDH1A1POLBHPGD
SCHEMBL11943902 0.74 ALDH1A1 (0.46) KDM4EHSD17B10ALDH1A1KMT2AMAPT
SCHEMBL11943907 0.74 ALDH1A1 (0.47) KDM4EHSD17B10ALDH1A1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA KDM4E 1548/4885HSD17B10 1101/4885ALDH1A1 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback